Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)

Trial Profile

Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary) ; 3BNC 117; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms eCLEAR
  • Most Recent Events

    • 10 Oct 2019 Planned primary completion date changed from 20 Jan 2020 to 20 Mar 2020.
    • 12 Apr 2019 Planned End Date changed from 14 Nov 2018 to 20 Apr 2021.
    • 12 Apr 2019 Planned primary completion date changed from 20 Jan 2019 to 20 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top